The AGENT clinical trials programme

European Heart Journal, Supplement

Volumn 6, Issue E, 2004, Pages

  Grines, C L ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Adenovirus; Angiogenesis; Clinical trials; Fibroblast growth factor; Myocardial ischaemia; Stable angina

Indexed keywords

ADENOVIRUS VECTOR; ANTIANGINA PECTORIS AGENT; FIBROBLAST GROWTH FACTOR 4; FIBROBLAST GROWTH FACTOR 5; GLYCERYL TRINITRATE; PLACEBO; RECOMBINANT FIBROBLAST GROWTH FACTOR;

ANGINA PECTORIS; ANGIOGENESIS; ATHEROSCLEROSIS; BODY TEMPERATURE DISORDER; CLINICAL TRIAL; COLLATERAL CIRCULATION; CONFERENCE PAPER; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; EDEMA; EXERCISE TEST; EXERCISE TOLERANCE; GENE THERAPY; HEART MUSCLE PERFUSION; HEART SIZE; HUMAN; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; RETINA NEOVASCULARIZATION; RETINOPATHY; STABLE ANGINA PECTORIS; TREADMILL EXERCISE; VIRUS EXPRESSION;

EID: 4043162086     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ehjsup.2004.06.002     Document Type: Conference Paper

References (10)

1. Lazarous D.F., Shou M., Stiber J.A., et al. Pharmacodynamics of basic fibroblast growth factor: route of administration determines myocardial and systemic distribution. Cardiovasc. Res. 36(1):1997;78-85
2. Henry T.D., Annex B.H., McKendall G.R., et al. The VIVA trial: vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation. 107:2003;1359-1365
3. Ruel M., Laham R.J., Parker J.A., et al. Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J. Thorac. Cardiovasc. Surg. 124:2002;28-34
4. Giordano F.J., Ping P., McKirnan M.D., et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat. Med. 2:1996;534-539
5. Grines C.L., Watkins M.W., Helmer G., et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation. 105:2002;1291-1297
6. Grines C.L., Watkins M.W., Mahmarian J.J., et al. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J. Am. Coll. Cardiol. 42:2003;1339-1347
7. Isner J.M., Vale P.R., Symes J.F., Losordo D.W. Assessment of risks associated with cardiovascular gene therapy in human subjects. Circ. Res. 89:2001;389-400
8. Ylä-Herttuala S., Martin J.F. Cardiovascular gene therapy. Lancet. 355:2000;213-222
9. Watkins M., Kleiman N., Helmer G., et al. Intracoronary angiogenic gene therapy is well tolerated in patients with coronary artery disease. Eur. Heart J. 24(suppl):2003;P1182. (Poster)
10. Grines C., Rubanyi G.M., Kleiman N.S., et al. Angiogenic gene therapy with adenovirus 5 fibroblast growth factor-4 (Ad5FGF-4): a new option for the treatment of coronary artery disease. Am. J. Cardiol. 92(Suppl.):2003;24N-31N